Rajendra S Pradhan

Learn More
WHAT IS KNOWN AND OBJECTIVE Navitoclax, a first-in-class small molecule Bcl-2 family inhibitor, is metabolized in vitro by the hepatic microsomal cytochrome P450 (CYP) enzymes CYP3A4. Drugs that(More)
BACKGROUND AND OBJECTIVE A pharmacokinetic substudy was conducted within a phase 3 clinical trial that evaluated the efficacy and safety of two leuprolide acetate 3-month depot formulations in(More)